西洛他唑用于卒中二级预防:历史、证据、局限与可能
西洛他唑是PDE3抑制剂,在亚洲多国获批用于非心源性卒中二级预防,试验显示可减少卒中复发,获益在治疗60至90天后出现。但既往试验存在开放标签设计、提前终止、失访多、缺乏功能或认知结局数据、仅在亚洲入组等局限,未改变西方国家临床实践或指南。需在更广泛人群中开展双盲安慰剂对照随机试验。
要点
- 西洛他唑在亚洲获批用于非心源性卒中二级预防,可减少卒中复发。
- 获益在治疗60至90天后出现,与多效性作用一致。
- 单用或联用阿司匹林/氯吡格雷不增加大出血风险,但头痛、胃肠道症状和心悸导致6%停药率增加。
核心结论
- 西洛他唑在亚洲试验中减少非心源性卒中复发,但既往试验局限使其未改变西方临床实践或指南。
研究设计与样本
- 本文为综述,总结西洛他唑用于卒中二级预防的历史、证据、局限与可能。
主要发现
- 西洛他唑获益在治疗60至90天后出现,与其对血小板聚集、血管重塑、血流和血脂的多效性作用一致。
- 西洛他唑单用或联用阿司匹林或氯吡格雷不增加大出血风险。
- 在大型二级卒中预防试验CSPS.com中,随机分配至西洛他唑的患者因头痛、胃肠道症状和心悸导致6%的停药率增加。
关键数值与推荐
- 西洛他唑获FDA和EMA批准用于外周动脉疾病患者跛行治疗。
- 西洛他唑在亚洲多国获批用于卒中二级预防。
临床怎么用
- 西洛他唑可用于非心源性卒中二级预防,尤其亚洲人群,但需注意头痛、胃肠道症状和心悸等不良反应。
- 西方指南尚未推荐西洛他唑用于卒中二级预防,临床决策需结合地域证据和患者耐受性。
局限性
- 既往试验存在开放标签设计、提前终止、大量失访、缺乏功能或认知结局数据、仅在亚洲入组等局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cilostazol is a PDE3 (phosphodiesterase III) inhibitor with a long track record of safety that is Food and Drug Administration and European Medicines Agency approved for the treatment of claudication in patients with peripheral arterial disease. In addition, cilostazol has been approved for secondary stroke prevention in several Asian countries based on trials that have demonstrated a reduction in stroke recurrence among patients with noncardioembolic stroke. The onset of benefit appears after 60 to 90 days of treatment, which is consistent with cilostazol's pleiotropic effects on platelet aggregation, vascular remodeling, blood flow, and plasma lipids. Cilostazol appears safe and does not increase the risk of major bleeding when given alone or in combination with aspirin or clopidogrel. Adverse effects such as headache, gastrointestinal symptoms, and palpitations, however, contributed to a 6% increase in drug discontinuation among patients randomized to cilostazol in a large secondary stroke prevention trial (CSPS.com [Cilostazol Stroke Prevention Study for Antiplatelet Combination]). Due to limitations of prior trials, such as open-label design, premature trial termination, large loss to follow-up, lack of functional or cognitive outcome data, and exclusive enrollment in Asia, the existing trials have not led to a change in clinical practice or guidelines in Western countries. These limitations could be addressed by a double-blind placebo-controlled randomized trial conducted in a broader population. If positive, it would increase the evidence in support of long-term treatment with cilostazol for secondary prevention in the millions of patients worldwide who have experienced a noncardioembolic ischemic stroke.
引用
- de Havenon A, Sheth KN, Madsen TE, et al. Cilostazol for Secondary Stroke Prevention: History, Evidence, Limitations, and Possibilities. Stroke. 2021. PMID: 34517768. doi:10.1161/STROKEAHA.121.035002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。